Long-term toxicity of cisplatin in germ-cell tumor survivors

Chovanec, Michal; Zaid, Mohammad Abu; Hanna, Nasser H.; El-Kouri, N.; Einhorn, Lawrence H.; Albany, Costantine

doi:10.1093/annonc/mdx360

Cited by 155 publications

(101 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…59,65,[69][70][71][72] However, late consequences of cisplatin-based chemotherapy, such as hearing damage and loss, cardiovascular conditions, hypertension, and neuropathy, have been reported during long-term follow-up. [73][74][75][76][77][78][79][80][81] Therefore, 1 cycle of BEP is recommended due to its lower toxicity. Surveillance is also a recommended primary treatment option for patients with stage I nonseminoma with risk factors.…”

Section: Primary Treatment Of Nonseminoma Stage I With Risk Factorsmentioning

confidence: 99%

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Gilligan

Lin

Aggarwal

et al. 2019

Journal of the National Comprehensive Cancer Network

194

213

View full text Add to dashboard Cite

Testicular cancer is relatively uncommon and accounts for ,1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nervesparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with .50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.

show abstract

Section: Primary Treatment Of Nonseminoma Stage I With Risk Factorsmentioning

confidence: 99%

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Gilligan

Lin

Aggarwal

et al. 2019

Journal of the National Comprehensive Cancer Network

194

213

View full text Add to dashboard Cite

show abstract

“…This substance induces vasospasm, increased aggregability of thrombocytes, increased levels of von Willebrand factor and hypomagnesemia. The cardiotoxicity of platinum derivatives can be also late (1,8,9). Cisplatin used to be detectable in plasma 10-20 years after completion of therapy, while it could continually stimulate endothelium and increase the risk of atherosclerosis (10).…”

Section: Cardiotoxic Effects Of Classic Anticancer Agents With a Focumentioning

confidence: 99%

“…An increased incidence of hyperlipidemia was found among men treated for testicular cancer, which appears to be associated with RT and/or chemotherapy (8,19).…”

Section: Tab 1 Targeted Anticancer Agents Associated With the Riskmentioning

confidence: 99%

Atherosclerosis in cancer patients

Mladosievičová¹,

Petríková²,

Valaskova³

et al. 2019

BLL

Self Cite

View full text Add to dashboard Cite

Cancer-related mortality have been declining in the last decades. Approximately half of adults and more than two thirds of children oncological patients live longer than 5 years after diagnosis. However, this optimistic scenario has been counterbalanced by an increasing cardiovascular risk in cancer patients. Atherosclerotic damage has been underestimated in oncology practice for a long time, but recently a signifi cant number of cancer patients with cardiovascular risk factors and serious artery disease during and after anticancer therapy has been reported. Complexity of atherosclerosis in cancer patients is challenging. Herein, we describe cardiovascular risk factors and pathophysiological mechanisms of atherosclerosis induced by selected classic chemotherapeutics, targeted cancer therapies, hormonal agents and radiotherapy and new clinical data regarding atherosclerosis, which received a particular attention in recent years (Tab. 1, Ref. 26). Text in PDF www.elis.sk.

show abstract

“…Patients presenting with metastatic disease historically had a poor prognosis until the introduction of cisplatin based chemotherapy, improving overall survival rates to approximately 80% 9. Nevertheless, these patients require monitoring for adverse consequences of cisplatin based therapy, including peripheral neuropathy, cardiopulmonary toxicity, secondary malignancies (mesothelioma, lung, colon, and bladder cancer), renal toxicity, hypogonadism, and infertility 10. Long term observation for disease recurrence includes imaging, serial monitoring of α fetoprotein levels, and physical examination (including consideration of rectal examination) every 3-6 months for five years after treatment 2…”

Section: Answersmentioning

confidence: 99%